The results of Dupixent’s first pivotal chronic obstructive pulmonary disease (COPD) trial were good; the results of the second look even better. Top-line data from the Phase III NOTUS trial showed a significant 34% reduction in exacerbations over placebo at one year, beating the 30% seen in the identical BOREAS trial back in March (Also see "Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD" - Scrip, 23 March, 2023.).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?